Protocol Ledger

NCT05931276 · Phase III · RECRUITING

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Interventional Phase III clinical trial protocol NCT05931276 sponsored by VA Office of Research and Development in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-22 Enrollment: 2,540 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05931276
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,540 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05931276
Protocol FieldVerified Registry Value
NCT IdentifierNCT05931276
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment2,540 participants (ESTIMATED)
Registered Start Date2024-05-22
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI